Followers | 19 |
Posts | 783 |
Boards Moderated | 0 |
Alias Born | 06/23/2020 |
Saturday, July 10, 2021 11:38:34 AM
From what I've researched about mRNA tech, it was ahead of its time back in 2015 when Dr Koos, Dr Helen S., and several others were working together at RGBP. Unfortunately they were too ahead of the times with their mRNA tech. Nobody willing to fund it.
Enter COVID-19 and Pfizer. Pfizer's mRNA vaccine brought a lot more value to mRNA tech. It's the hot new toy on the play ground and everybody wants it.
So why was Dr. Koos reinstated now? The answer seems obvious. Their mRNA tech was costing them money and wasn't going anywhere, but times have changed. mRNA technology is the future and treating cancer is the holy grail. He was reinstated to bring the company back current in order to sell it. The new patent solidified their hold on it. Now it's a matter of when the RM/BO happens.
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM